Xeligekimab is a recombinant fully human monoclonal antibody that specifically targets interleukin-17A (IL-17A). It is also known by the development code GR1501 and belongs to the class of targeted anti-IL-17A biological therapies. Xeligekimab is designed to bind IL-17A and inhibit its interaction with the IL-17A receptor, thereby reducing IL-17A-mediated inflammatory signaling.
Xeligekimab is a human IgG4 monoclonal antibody and has been developed for inflammatory and immune-mediated diseases, particularly moderate-to-severe plaque psoriasis. China approved Xeligekimab Injection under the trade name 金立希 (Jin Li Xi) for adults with moderate-to-severe plaque psoriasis who are candidates for systemic treatment or phototherapy.
Xeligekimab is a large recombinant protein rather than a conventional low-molecular-weight chemical API. Its reported molecular weight is approximately 145.66 kDa. The compound is identified by CAS Number 2382921-73-3 and is described as a human IgG4 kappa antibody.
The antibody is also referred to as GR1501 in pharmaceutical research and clinical-development literature. Its molecular structure is designed to selectively recognize IL-17A, an inflammatory cytokine involved in the pathogenesis of psoriasis and other immune-mediated inflammatory disorders.
Because Xeligekimab is a monoclonal antibody, its identity is defined primarily by its antibody sequence, molecular mass, structural characteristics, antigen-binding properties and biological activity rather than by a conventional small-molecule molecular formula.
Xeligekimab is an IL-17A antagonist. It binds specifically to IL-17A and prevents the cytokine from interacting with the IL-17 receptor.
IL-17A plays an important role in inflammatory signaling and contributes to the recruitment and activation of inflammatory cells and production of inflammatory mediators. Blocking IL-17A can therefore reduce downstream inflammatory activity.
Biochemical characterization has reported high-affinity binding of Xeligekimab to recombinant human IL-17A and IL-17A/F, with reported equilibrium dissociation constants of approximately 0.139 nM and 2.47 nM, respectively.
This mechanism places Xeligekimab within the targeted anti-IL-17A monoclonal antibody class.
Xeligekimab API is relevant to biotechnology companies, pharmaceutical manufacturers, biological formulation developers and research organizations working on targeted inflammatory and autoimmune therapies.
As a Xeligekimab API manufacturer and supplier in India, the product can be positioned for pharmaceutical development, biological research and manufacturing applications requiring controlled-quality recombinant monoclonal antibody material.
Because Xeligekimab is a biological API, quality control should focus on protein-specific attributes including antibody identity, purity, protein concentration, aggregation, charge variants, molecular integrity, host-cell proteins, residual host-cell DNA, endotoxins, bioburden and biological activity.
Xeligekimab is approved in China for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. The China NMPA describes Xeligekimab Injection as a recombinant fully human IgG4 anti-IL-17A monoclonal antibody.
Clinical development has also investigated Xeligekimab in other inflammatory conditions. Studies have evaluated the molecule in psoriatic arthritis and axial spondyloarthritis, reflecting the importance of IL-17A signaling in these inflammatory diseases.
For pharmaceutical development, Xeligekimab can therefore be categorized as an anti-IL-17A biological API, monoclonal antibody API, psoriasis API, immunology API and recombinant therapeutic antibody.
Xeligekimab is a recombinant monoclonal antibody with a reported molecular weight of approximately 145.66 kDa. Research-grade product information describes it as a liquid with a colorless to light-yellow appearance.
The antibody is described as a human IgG4 kappa molecule. Because it is a protein biological, conventional small-molecule characteristics such as a defined melting point, residue on ignition and loss on drying are not appropriate primary API specifications.
Xeligekimab is normally supplied in an aqueous or buffer-based formulation for research or pharmaceutical applications. The exact buffer composition and concentration can vary according to the particular product and manufacturing specification.
Quality control of Xeligekimab should use analytical methods specifically designed for recombinant monoclonal antibodies.
SEC-HPLC can be used to evaluate aggregation and molecular-size variants, while SDS-PAGE can support protein integrity and purity assessment. Peptide mapping and mass spectrometry can be used for molecular identity and structural characterization.
Additional quality attributes may include charge heterogeneity, glycosylation profile, protein concentration, host-cell proteins, residual host-cell DNA, endotoxin, bioburden, visible particles and subvisible particles.
Biological activity should be demonstrated using an appropriate validated binding or cell-based functional assay measuring the ability of Xeligekimab to interact with and neutralize IL-17A.
Xeligekimab, also known as GR1501, was developed as a fully human IgG4 monoclonal antibody targeting IL-17A.
Clinical development has included randomized studies in moderate-to-severe plaque psoriasis. A Phase II study evaluated 100 mg, 150 mg and 200 mg doses administered every four weeks during the initial treatment period and subsequently evaluated maintenance regimens.
Xeligekimab has also been investigated in axial spondyloarthritis. A Phase III study evaluated 100 mg and 200 mg treatment groups and reported clinical outcomes through 48 weeks.
These development programs reflect the broader application of IL-17A-targeted biological therapies in inflammatory diseases.
Xeligekimab is a recombinant monoclonal antibody produced using biological expression and purification processes appropriate for therapeutic proteins.
Manufacturing of a pharmaceutical-grade antibody requires controlled cell-culture production, harvesting, purification and appropriate viral-safety controls. Downstream processing must maintain the structural integrity and biological activity of the antibody.
Important manufacturing controls include protein concentration, purity, aggregate levels, charge variants, glycosylation, host-cell protein removal, residual DNA, endotoxin and bioburden.
The final formulation and container-closure system should be established according to validated stability data and the applicable pharmaceutical specification.
Xeligekimab biological material should be stored according to the applicable product specification and certificate of analysis.
Research-grade Xeligekimab is supplied under controlled cold-chain conditions, with storage recommendations determined by the specific formulation and lot. The product information recommends following the lot-specific certificate of analysis for storage conditions.
Because monoclonal antibodies can be affected by aggregation, denaturation and repeated freeze-thaw cycles, appropriate temperature control and handling procedures are important.
Pharmaceutical-grade Xeligekimab should be stored according to validated stability data and approved product requirements.
Xeligekimab is a specialized recombinant monoclonal antibody targeting IL-17A. Its development and approval in China make it a relevant biological API for pharmaceutical development involving inflammatory and immune-mediated diseases.
For pharmaceutical manufacturers and biotechnology developers, quality control should focus on identity, protein concentration, purity, aggregate content, biological activity, charge variants, glycosylation, host-cell proteins, residual DNA, endotoxins and bioburden.
As a targeted biological ingredient, Xeligekimab can be positioned for applications involving anti-IL-17A therapies, psoriasis medicines, autoimmune disease research, recombinant monoclonal antibody development and pharmaceutical biotechnology.
| Parameter | Specification |
|---|---|
| Appearance | white to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 99.98% |
| Loss on Drying | NMT 1.0% |
| Residue on Ignition | NMT 0.1% |
| Melting Point | 150°C – 154°C |